Polaryx Therapeutics Inc. (PLYX)
PLYX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PLYX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002075320 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | WY |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These matters, along with the conditions described above, raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements were available to be issued." | 10-Q 2026-11-12 |
| Cash and burn | $8.4M cash; operating cash flow -$2.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 49,845,993 (2026-10-31). | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Edison, New Jersey, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $368K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$3.3M | -$3.1M | $8.4M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$1.4M | -$1.4M | $11.5M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$2.5M | -$2.1M | $3.1M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | Not filed | -$1.5M | -$1.5M | $5.1M | No debt tags | Needs four quarters | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | Not filed | -$1.4M | -$887K | Not filed | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$1.0M | -$858K | Not filed | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$5.1M | -$709K | Not filed | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2026-02-02 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-24 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-14 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-07-28 |
Source: SEC EDGAR submissions feed, 36 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.7% |
| 1 month | -8.8% |
| 3 months | -29.2% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -94.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RLYB | Rallybio Corporation | $15.43 | -1.88% | $86.4M |
| NKTX | Nkarta Inc. | $1.21 | +1.68% | $86.8M |
| GNLX | Genelux Corporation | $1.92 | +2.95% | $86.9M |
| KZIA | Kazia Therapeutics Limited | $5.60 | -15.41% | $87.1M |
| HURA | TuHURA Biosciences Inc. | $1.33 | -4.32% | $87.5M |
| ANIX | Anixa Biosciences Inc. | $2.55 | -2.67% | $88.6M |
| CPIX | Cumberland Pharmaceuticals Inc. | $5.21 | -11.39% | $78.1M |
| PMVP | PMV Pharmaceuticals Inc. | $1.19 | -6.30% | $89.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier